JPS59175439A - 繊維状赤血球凝集素の製法 - Google Patents
繊維状赤血球凝集素の製法Info
- Publication number
- JPS59175439A JPS59175439A JP58047268A JP4726883A JPS59175439A JP S59175439 A JPS59175439 A JP S59175439A JP 58047268 A JP58047268 A JP 58047268A JP 4726883 A JP4726883 A JP 4726883A JP S59175439 A JPS59175439 A JP S59175439A
- Authority
- JP
- Japan
- Prior art keywords
- medium
- bordetella pertussis
- culture
- glutathione
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000185 hemagglutinin Substances 0.000 title abstract description 5
- 101710154606 Hemagglutinin Proteins 0.000 title abstract description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title abstract description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title abstract description 4
- 101710176177 Protein A56 Proteins 0.000 title abstract description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 14
- 108010024636 Glutathione Proteins 0.000 claims abstract description 12
- 229960003180 glutathione Drugs 0.000 claims abstract description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 11
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 9
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 9
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 9
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 101710154643 Filamentous hemagglutinin Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- POJOORKDYOPQLS-UHFFFAOYSA-L barium(2+) 5-chloro-2-[(2-hydroxynaphthalen-1-yl)diazenyl]-4-methylbenzenesulfonate Chemical compound [Ba+2].C1=C(Cl)C(C)=CC(N=NC=2C3=CC=CC=C3C=CC=2O)=C1S([O-])(=O)=O.C1=C(Cl)C(C)=CC(N=NC=2C3=CC=CC=C3C=CC=2O)=C1S([O-])(=O)=O POJOORKDYOPQLS-UHFFFAOYSA-L 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 2
- 229930003268 Vitamin C Natural products 0.000 abstract description 2
- 239000005018 casein Substances 0.000 abstract description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 2
- 235000021240 caseins Nutrition 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 2
- 235000019154 vitamin C Nutrition 0.000 abstract description 2
- 239000011718 vitamin C Substances 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 28
- 201000005702 Pertussis Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000035931 haemagglutination Effects 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- -1 carboxymethyl cyclodextrin Chemical compound 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- HOXINJBQVZWYGZ-UHFFFAOYSA-N fenbutatin oxide Chemical compound C=1C=CC=CC=1C(C)(C)C[Sn](O[Sn](CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C1=CC=CC=C1 HOXINJBQVZWYGZ-UHFFFAOYSA-N 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58047268A JPS59175439A (ja) | 1983-03-23 | 1983-03-23 | 繊維状赤血球凝集素の製法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58047268A JPS59175439A (ja) | 1983-03-23 | 1983-03-23 | 繊維状赤血球凝集素の製法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59175439A true JPS59175439A (ja) | 1984-10-04 |
| JPS64929B2 JPS64929B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-01-10 |
Family
ID=12770546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58047268A Granted JPS59175439A (ja) | 1983-03-23 | 1983-03-23 | 繊維状赤血球凝集素の製法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59175439A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4849358A (en) * | 1987-04-24 | 1989-07-18 | The Research Foundation For Microbial Diseases Of Osaka University | Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine |
| EP0427462A1 (en) | 1989-11-06 | 1991-05-15 | SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.) | Process |
| JP2016530891A (ja) * | 2013-09-13 | 2016-10-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ボルデテラ属種の工業規模培養のための合成培地 |
-
1983
- 1983-03-23 JP JP58047268A patent/JPS59175439A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4849358A (en) * | 1987-04-24 | 1989-07-18 | The Research Foundation For Microbial Diseases Of Osaka University | Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine |
| EP0427462A1 (en) | 1989-11-06 | 1991-05-15 | SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.) | Process |
| JP2016530891A (ja) * | 2013-09-13 | 2016-10-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ボルデテラ属種の工業規模培養のための合成培地 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS64929B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Imaizumi et al. | Effect of heptakis (2, 6-O-dimethyl) beta-cyclodextrin on the production of pertussis toxin by Bordetella pertussis | |
| US4965205A (en) | Culture medium for bacteria of the bordetella genus containing etherified derivative of D-glucose and a cyclodextrin | |
| Wilkinson | The extracellular polysaccharides of bacteria | |
| Bales et al. | Purification and characterization of biofilm-associated EPS exopolysaccharides from ESKAPE organisms and other pathogens | |
| EP0120532A2 (en) | Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa | |
| EP0077646B1 (en) | Method of culturing microbes belonging to the genus bordetella and culture medium | |
| JPH05219942A (ja) | 細菌クロストリジウム・ヒストリチカムの変異株、その製造法及びその用途 | |
| JPS59175439A (ja) | 繊維状赤血球凝集素の製法 | |
| Rogers et al. | The effect of growth rate on the adhesion of the oral bacteria Streptococcus mutans and Streptococcus milleri | |
| Goel | New method for the isolation of membranes from Mycoplasma gallisepticum | |
| JP2660908B2 (ja) | ビフィズス菌増殖促進性及び生残性が良好なヨーグルト | |
| Fett et al. | A new bacterial agglutinin from soybean: II. evidence against a role in determining pathogen specificity | |
| Wachter et al. | Treponeme outer envelope: chemical analysis | |
| Imaizumi et al. | A new culturing method for production of filamentous hemagglutinin of Bordetella pertussis | |
| JPS59187778A (ja) | 微生物を培養するための培地 | |
| RU2518282C1 (ru) | Питательная среда для глубинного культивирования туляремийного микроба | |
| Chu et al. | Purification and characterization of a novel haemagglutinin from Chlorella pyrenoidosa | |
| Saito et al. | Effects of a Bacteriocin from Mycobacterium smegmatis on BALB/3T3 and Simian Virus 40‐Transformed BALB/c Mouse Cells | |
| Hedstrom et al. | Ethylenediaminetetraacetate-extractable protein-lipopolysaccharide complex of Pseudomonas aeruginosa: characterization of protein components | |
| JPS5963183A (ja) | ボルデテラ属に属する微生物の培養方法及び培地 | |
| RU2407792C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ IgAl-ПРОТЕАЗЫ ИЗ КУЛЬТУРЫ NEISSERIA MENINGITIDIS СЕРОГРУППЫ А И ИММУНОГЕННЫЙ ПРЕПАРАТ НА ЕЕ ОСНОВЕ | |
| Farrell et al. | Metabolic studies of streptococci | |
| Barriga et al. | Reduction of adhesion of a Lactobacillus sp. to collagen sausage casing by proteins | |
| JPS60155127A (ja) | 生物学的活性物質の製法 | |
| Harada et al. | Preliminary X-ray crystallographic study of lysozyme produced by Streptomyces globisporus |